Release Date: July 31, 2025
Expiration Date: July 31, 2026
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in atopic dermatitis. The OX40-OX40L interaction (2 co-stimulatory immune checkpoint molecules) plays a central role in the pathogenesis of atopic dermatitis. In this educational program, these experts review the evidence for the emerging role of OX40-OX40L axis inhibition in the treatment of patients with atopic dermatitis.
This educational activity is an archive of the live symposium held on June 7, 2025.
Target Audience
This educational activity is designed for dermatologists, allergists, immunologists, pediatricians, primary care physicians, nurse practitioners, physician assistants, and other health care professionals involved in the diagnosis, management, and treatment of patients with atopic dermatitis.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Outline the clinical rationale for the development of OX40 & OX40 ligand inhibitor–targeted therapies in the treatment of moderate-to-severe AD
- Analyze clinical trial efficacy and safety data for current and novel emerging OX40 & OX40 ligand inhibitor–targeted therapies in the treatment of moderate-to-severe AD
Johann Gudjonsson, MD, PhD
Arthur C. Curtis Professor of Molecular Skin Immunology
Professor of Dermatology, Department of Internal Medicine
University of Michigan
Director of Michigan Skin Research Center
Ann Arbor, Michigan
Disclosures: Grant & Research Support: AbbVie, Almirall, AnaptysBio, Johnson & Johnson, Merck, Sanofi/Regeneron; Consultant: AbbVie, Eli Lilly and Company, Johnson & Johnson, Merck, Sanofi/Regeneron; Adviser: Almirall, Zura Bio
Christopher Bunick, MD, PhD
Associate Professor of Dermatology and Translational Biomedicine
Yale School of Medicine
New Haven, CT
Disclosures: Consultant: AbbVie, Apogee Therapeutics, Arcutis Biotherapeutics, Eli Lilly and Company, Incyte, LEO Pharma, Pfizer, Sanofi; Investigator: AbbVie, Apogee Therapeutics, LEO Pharma
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here